Trial · NCT05040971
Results by group46
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 46
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Body Weight (Percentage [%]) | Semaglutide 2.4 mg | -14.4 | Standard Deviation 7.9 | Percentage (%) of body weight | |
| Change in Body Weight (Percentage [%]) | Placebo | -2.7 | Standard Deviation 4.3 | Percentage (%) of body weight | |
| Participants With Change to Normoglycemia | Semaglutide 2.4 mg | Normoglycemia | 103 | Participants | |
| Participants With Change to Normoglycemia | Placebo | Normoglycemia | 9 | Participants | |
| Participants With Change to Normoglycemia | Semaglutide 2.4 mg | Pre-diabetes | 23 | Participants | |
| Participants With Change to Normoglycemia | Placebo | Pre-diabetes | 53 | Participants | |
| Participants With Change to Normoglycemia | Semaglutide 2.4 mg | Type 2 diabetes | 1 | Participants | |
| Participants With Change to Normoglycemia | Placebo | Type 2 diabetes | 2 | Participants | |
| Change in Glycosylated Haemoglobin (HbA1c) | Semaglutide 2.4 mg | -0.4 | Standard Deviation 0.3 | Percentage of HbA1c | |
| Change in Glycosylated Haemoglobin (HbA1c) | Placebo | 0.1 | Standard Deviation 0.2 | Percentage of HbA1c | |
| Change in Fasting Plasma Glucose (FPG) | Semaglutide 2.4 mg | -0.8 | Standard Deviation 0.6 | millimoles per liter (mmol/L) | |
| Change in Fasting Plasma Glucose (FPG) | Placebo | -0.3 | Standard Deviation 0.7 | millimoles per liter (mmol/L) | |
| Change in Waist Circumference | Semaglutide 2.4 mg | -11.6 | Standard Deviation 8.7 | centimeter (cm) | |
| Change in Waist Circumference | Placebo | -2.8 | Standard Deviation 5.4 | centimeter (cm) | |
| Change in Systolic Blood Pressure | Semaglutide 2.4 mg | -9 | Standard Deviation 13 | millimeters of mercury (mmHg) | |
| Change in Systolic Blood Pressure | Placebo | -1 | Standard Deviation 13 | millimeters of mercury (mmHg) | |
| Change in Triglycerides (Millimoles Per Liter [mmol/L]) - Ratio to Baseline | Semaglutide 2.4 mg | 0.80 | Geometric Coefficient of Variation 36.4 | Ratio of triglycerides | |
| Change in Triglycerides (Millimoles Per Liter [mmol/L]) - Ratio to Baseline | Placebo | 0.96 | Geometric Coefficient of Variation 30.6 | Ratio of triglycerides | |
| Change in Total Cholesterol (mmol/L) - Ratio to Baseline | Semaglutide 2.4 mg | 0.94 | Geometric Coefficient of Variation 16.1 | Ratio of total cholesterol | |
| Change in Total Cholesterol (mmol/L) - Ratio to Baseline | Placebo | 1.01 | Geometric Coefficient of Variation 15.7 | Ratio of total cholesterol |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05040971/results